The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Galectin Therapeutics Inc(NASDAQ:GALT) 
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharid...
Website: http://galectintherapeutics.com
Founded: 2000
Full Time Employees: 4
Sector: Healthcare
Industry: Biotechnology
Galectin Therapeutics Days Payable Outstanding ttm (DPO)
Galectin Therapeutics Op Cashflow Per Share ttm
Galectin Therapeutics Free Cashflow Per Share ttm
Galectin Therapeutics Cash Per Share ttm
Galectin Therapeutics (GAAP) P/E ratio ttm
Galectin Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.